← Back to Patent Explorer
US4760131A Expired / Lapsed US ⏱️ 0.0 years remaining

Wound-healing composition

Assignee: Celtrix Pharmaceuticals Inc
•
Filing: 1986-06-23
•
Granted: 1988-07-26
•
Expires: 2006-06-23
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A soft tissue wound healing composition comprising an aqueous mixture of fibrillar collagen, heparin, and undegranulated platelets or platelet releasate. The composition is applied topically to the wound site in conjunction with means to keep it at the site and hydrated or in the form of an occlusive dressing.

Inventors

  • 👤 John S. Sundsmo
  • 👤 George A. Ksander
  • 👤 John M. McPherson

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 03:32
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/39; Y; Y10; Y10S; Y10S128/00; Y10S128/08

Claims Analysis

Total Claims: 29
Claim 1
Independent Claim 76 words
A soft tissue wound healing composition comprising an aqueous mixture of: (a) fibrillar collagen at a concentration in the range of about 1 to about 70 mg/ml; (b) about 0.1% to about 10% by weight based on collagen of a glycosaminoglycan selected from the group consisting of heparin, a heparin-like glycosaminoglycan, and mixtures thereof; and (c) about 0.01% to about 10% by volume based on collagen of undegranulated platelets or an equivalent amount of platelet releasate.
Claim 2
Dependent Claim 76 words
A soft tissue wound healing composition comprising an aqueous mixture of: (a) fibrillar collagen at a concentration in the range of about 1 to about 70 mg/ml; (b) about 0.1% to about 10% by weight based on collagen of a glycosaminoglycan selected from the group consisting of heparin, a heparin-like glycosaminoglycan, and mixtures thereof; and (c) about 0.01% to about 10% by volume based on collagen of undegranulated platelets or an equivalent amount of platelet releasate.
Claim 3
Dependent Claim 81 words
A composition for promoting fibroplasia at a soft tissue wound site comprising an aqueous mixture of: (a) fibrillar collagen at a concentration in the range of about 1 to about 70 mg/ml; (b) about 0.1% to about 10% by weight based on collagen of a glycosaminoglycan selected from the group consisting of heparin, a heparin-like glycosaminoglycan, and mixtures thereof; and (c) about 0.01% to about 10% by volume based on collagen of undegranulated platelets or an equivalent amount of platelet releasate.
Claim 4
Dependent Claim 81 words
A composition for promoting fibroplasia at a soft tissue wound site comprising an aqueous mixture of: (a) fibrillar collagen at a concentration in the range of about 1 to about 70 mg/ml; (b) about 0.1% to about 10% by weight based on collagen of a glycosaminoglycan selected from the group consisting of heparin, a heparin-like glycosaminoglycan, and mixtures thereof; and (c) about 0.01% to about 10% by volume based on collagen of undegranulated platelets or an equivalent amount of platelet releasate.
Claim 5
Dependent Claim 81 words
A composition for promoting reepithelialization at a soft tissue wound site comprising an aqueous mixture of: (a) fibrillar collagen at a concentration in the range of about 1 to about 70 mg/ml; (b) about 0.1% to about 10% by weight based on collagen of a glycosaminoglycan selected from the group consisting of heparin, a heparin-like glycosaminoglycan, and mixtures thereof; and (c) about 0.01% to about 10% by volume based on collagen of undegranulated platelets or an equivalent amount of platelet releasate.
Claim 6
Dependent Claim 81 words
A composition for promoting reepithelialization at a soft tissue wound site comprising an aqueous mixture of: (a) fibrillar collagen at a concentration in the range of about 1 to about 70 mg/ml; (b) about 0.1% to about 10% by weight based on collagen of a glycosaminoglycan selected from the group consisting of heparin, a heparin-like glycosaminoglycan, and mixtures thereof; and (c) about 0.01% to about 10% by volume based on collagen of undegranulated platelets or an equivalent amount of platelet releasate.
Claim 7
Dependent Claim 81 words
A composition for promoting vascularization at a soft tissue wound site comprising an aqueous mixture of: (a) fibrillar collagen at a concentration in the range of about 1 to about 70 mg/ml; (b) about 0.1% to about 10% by weight based on collagen of a glycosaminoglycan selected from the group consisting of heparin, a heparin-like glycosaminoglycan, and mixtures thereof; and (c) about 0.01% to about 10% by volume based on collagen of undegranulated platelets or an equivalent amount of platelet releasate.
Claim 8
Dependent Claim 81 words
A composition for promoting vascularization at a soft tissue wound site comprising an aqueous mixture of: (a) fibrillar collagen at a concentration in the range of about 1 to about 70 mg/ml; (b) about 0.1% to about 10% by weight based on collagen of a glycosaminoglycan selected from the group consisting of heparin, a heparin-like glycosaminoglycan, and mixtures thereof; and (c) about 0.01% to about 10% by volume based on collagen of undegranulated platelets or an equivalent amount of platelet releasate.
Claim 9
Dependent Claim 61 words
A cutaneous wound healing composition comprising an aqueous mixture of: (a) fibrillar collagen at a concentration in the range of about 1 to about 70 mg/ml; (b) about 0.1% to about 10% by weight based on collagen of heparin; and (c) about 0.01% to about 10% by volume based on collagen of undegranulated platelets or an equivalent amount of platelet releasate.
Claim 10
Dependent Claim 61 words
A cutaneous wound healing composition comprising an aqueous mixture of: (a) fibrillar collagen at a concentration in the range of about 1 to about 70 mg/ml; (b) about 0.1% to about 10% by weight based on collagen of heparin; and (c) about 0.01% to about 10% by volume based on collagen of undegranulated platelets or an equivalent amount of platelet releasate.
Claim 11
Dependent Claim 18 words
The composition of claim 5 wherein the collagen is Type I collagen, Type III collagen, or mixtures thereof.
Claim 12
Dependent Claim 13 words
The composition of claim 6 wherein the fibrillar collagen is reconstituted fibrillar collagen.
Claim 13
Dependent Claim 20 words
The composition of claim 5 wherein the concentration of fibrillar collagen is in the range of 15 to 35 mg/ml.
Claim 14
Dependent Claim 55 words
The composition of claim 5 wherein the amount of heparin in the composition is in the range of 0.3% to 3% by weight based on collagen and the amount of undegranulated platelets is 2% to 10% by volume based on collagen and the amount of platelet releasate is equivalent to said amount of undegranulated platelets.
Claim 15
Dependent Claim 65 words
The composition of claim 5 wherein the collagen is reconstituted xenogeneic collagen, the concentration of collagen is in the range of 15 to 35 mg/ml, the heparin constitutes about 1% by weight based on collagen, and the amount of undegranulated platelets is about 2% to 10% by volume based on collagen and the amount of platelet releasate is equivalent to said amount of undegranulated platelets.
Claim 16
Dependent Claim 22 words
A cutaneous wound dressing comprising a composite of (a) a solid support on which is carried (b) the composition of claim 5.
Claim 17
Dependent Claim 22 words
A cutaneous wound dressing comprising a composite of (a) a solid support on which is carried (b) the composition of claim 6.
Claim 18
Dependent Claim 22 words
A cutaneous wound dressing comprising a composite of (a) a solid support on which is carried (b) the composition of claim 7.
Claim 19
Dependent Claim 22 words
A cutaneous wound dressing comprising a composite of (a) a solid support on which is carried (b) the composition of claim 8.
Claim 20
Dependent Claim 22 words
A cutaneous wound dressing comprising a composite of (a) a solid support on which is carried (b) the composition of claim 9.
Claim 21
Dependent Claim 22 words
A cutaneous wound dressing comprising a composite of (a) a solid support on which is carried (b) the composition of claim 10.
Claim 22
Dependent Claim 34 words
A method of promoting healing of a soft tissue wound comprising applying the composition of claim 1 to the wound site in conjunction with means for keeping the composition at the site and hydrated.
Claim 23
Dependent Claim 24 words
The method of claim 17 wherein the soft tissue wound is a cutaneous wound, a dermal wound, a mucosal wound, or an epithelial wound.
Claim 24
Dependent Claim 34 words
A method of promoting healing of a cutaneous wound comprising applying the composition of claim 5 to the wound site in conjunction with a dressing that keeps the composition at the site and hydrated.
Claim 25
Dependent Claim 34 words
A method of promoting healing of a cutaneous wound comprising applying the composition of claim 6 to the wound site in conjunction with a dressing that keeps the composition at the site and hydrated.
Claim 26
Dependent Claim 34 words
A method of promoting healing of a cutaneous wound comprising applying the composition of claim 7 to the wound site in conjunction with a dressing that keeps the composition at the site and hydrated.
Claim 27
Dependent Claim 34 words
A method of promoting healing of a cutaneous wound comprising applying the composition of claim 8 to the wound site in conjunction with a dressing that keeps the composition at the site and hydrated.
Claim 28
Dependent Claim 34 words
A method of promoting healing of a cutaneous wound comprising applying the composition of claim 9 to the wound site in conjunction with a dressing that keeps the composition at the site and hydrated.
Claim 29
Dependent Claim 34 words
A method of promoting healing of a cutaneous wound comprising applying the composition of claim 10 to the wound site in conjunction with a dressing that keeps the composition at the site and hydrated.

References Cited (Backward Citations)

US3694161A Cited
US4060081A Cited
US4453939A Cited
US4350629A Cited
US4418691A Cited
US4458678A Cited
US4505266A Cited
US4448718A Cited
EP0154447A2 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1991-07-26 1992-01-25 1992-07-26 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1995-07-26 1996-01-25 1996-07-26 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1999-07-26 2000-01-25 2000-07-26 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag